Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Essilorluxottica
Thumbnail
July 02, 2020

Covid-19 divides the biggest medtechs

Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.

Thumbnail
August 02, 2018

Medtechs prioritise efficiency when it comes to hiring

Big cap medtech is hiring, largely thanks to organic growth.

Vantage logo
May 02, 2018

Medtech in 2024: six years of stability, or as wild as the past?

Article image
Vantage logo
January 09, 2018

2017 saw the stars Align for big-cap medtech

Toothy grins all round at Align, but it is unclear how much longer it can keep up its scorching rate of sales growth.

Article image
Vantage logo
July 04, 2017

Startling reversal of fortunes as large-cap medtechs soar

Vantage logo
October 17, 2016

Medtech to hit $530bn in 2022, fuelled by diagnostics and neurology

Vantage logo
February 18, 2016

Novartis hopes Transcend buy will relieve the pressure on Alcon

Vantage logo
January 12, 2016

Big-cap medtech shares stutter

Vantage logo
August 05, 2015

Fewer, but bigger: medtech jobs jump thanks to mergers

Vantage logo
July 07, 2015

Big-cap medtech shares fall as atmosphere cools

Vantage logo
January 19, 2015

Best is yet to come as medtech mergers come roaring back

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.